North of Scotland Clinical Management Guideline (CMG): Ovarian Cancer		
Lead Group: North Cancer Gynaecology Pathway Board (NCGPB) Lead Author: Dr Mahalakshmi Gurumurthy (NHS Grampian) Lead Coordinator: Serena Venegoni (NCA)	File Reference: NCA-CMG-OVA Ovarian_V26 Published: 01/05/2024 Approved: 03/04/24	
For symptoms of suspected Gynaecological cancer, please refer to the <u>Scottish Referral Guidelines for Suspected Cancer</u>		
<u>Contents</u>	Staging	
Page 2 - Diagnosis of Ovarian Cancer	All patients with a confirmed diagnosis of ovarian cancer will have	
Page 3 – Treatment Overview	their cancer staged using the FIGO system as documented on Page 8	
Page 4 – Inclusion / Exclusion criteria for surgery of this CMG.		
Page 5 – Management of relapsed disease		
Page 6 – Follow-Up of Ovarian Cancer patients Cancer staging will allow a clinical decision on treatment of		
Page 7 – Pathological staging criteria (FIGO)	be made in accordance with the guidance provided by this CMG in	
Page 8 – List of SACT regimens	the management of patients aged 18 years and older with ovarian	
Page 9 – Definitions	cancer.	
Addendum on management during COVID pandemic		

## General Principles

Referrals should be vetted in accordance with the Scottish Referral Guidelines for Suspected Cancer.

All patients must be discussed at MDT meetings throughout their patient journey as required.

All patients referred for investigation of symptoms potentially indicative of ovarian cancer should receive an appointment to a specialist outpatient gynaecology clinic.

All patients should be considered for surgery at MDT using the exclusions / inclusions on Page 5 to determine suitability.

Where available, clinical trials should always be considered as the preferred option for all eligible patients and consideration given to national referral.

Patients must be involved in all decision-making relating to their care with informed consent required for patients undergoing treatment. A list of SACT regimens is provided (page 9).

Full regional SACT Protocols will be developed and linked to from this document.

Patients in follow-up will have access to a clinical nurse specialist throughout their follow-up and post-discharge for any further symptoms relating to treatment for ovarian cancer.

Patients will have a Holistic Needs Assessment undertaken as part of their pathway.

## Pre-Referral Investigations undertaken in Primary Care

Urgent Suspicion of Ovarian Cancer Referrals
Abnormal ultrasound scan and/or CA125 level
Ascites and/or ultrasound-confirmed pelvic or abdominal mass (that is not obviously uterine fibroids, gastrointestinal or urological in origin
Good Practice Points: An abdominal palpation should be undertaken, CA125 blood serum level measured and urgent pelvic ultraso und scan carried
out in:
any woman over 50 years who has experienced new symptoms within the last 12 months that suggest irritable bowel syndrome or women (especial
those over 50 years) with one or more unexplained and recurrent symptoms (most days) of:
- Abdominal distension or persistent bloating
- Feeling full quickly or difficulty eating
- Loss of appetite
- Pelvic or abdominal pain
- Increased urinary urgency and/or frequency
- Change in bowel habit
Primary care managment

Symptoms (as above) persisting or worsening for any woman who has a normal CA125 with normal ultrasound, assess for other clinical causes and investigate as appropriate or refer to appropriate secondary care services, depending on local arrangement.

Refer urgently or routinely, if symptoms persist, depending on the symptoms and the degree of concern about cancer.

# North Cancer Alliance

#### **Diagnosis of Ovarian Cancer**


#### All Patients: Initial Investigations


Full medical history

Physical examination including Pelvis

Routine blood screen (Full Blood Count, biochemistry, CA125 and CEA; other germ cell tumour markers if indicated for women under 40)

If germ cell tumour, follow national guidelines for female germ cell tumour





## North of Scotland Clinical Management Guideline (CMG): Inclusion & Exclusion Criteria Last Updated 05/04/2024




	INCLUSIONS 1: Decisio	on-making for Up Front Surgery (UFS)	EXCLUSIONS
•	<ul> <li>Patients of all stages considered (able to be resected to &lt;1cm residual disease)Biopsy proven low grade or clear cell advanced ovarian cancer (chemo resistant) should have primary surgery where feasible</li> <li>All extra-abdominal metastases (stage IV) should be considered potential indications for NACT/IDS, not primary surgery, except for the following: <ul> <li>Resectable inguinal lymph nodes</li> <li>Pleural fluid that contains cytologically malignant cells without proof of the presence of pleural tumours (IVA).</li> <li>Where considering the clinical significance of cardiophrenic nodes</li> </ul> </li> </ul>	<ul> <li>Abdominal exclusion criteria:</li> <li>Involvement of the root of the small bowel mesentery</li> <li>Diffuse and confluent carcinomatosis of the stomach and/or small bowel that lead to a short bowel syndrome or a total gastrectomy</li> <li>Intrahepatic metastases</li> <li>Infiltration of the porta hepatis, duodenum and/or pancreas and/or the large of coeliac trunk</li> <li>Patient characteristics:</li> <li>Impaired performance status and comorbidity that does not allow a maximal se</li> <li>Patients' nonacceptance of potential supportive measures, such as blood trans</li> <li>Significant recent arterial or venous clot &lt;3months e.g. CVA, PE</li> <li>Disease requiring ultra-radical surgery (NICE guidance 470) i.e. multiple resect gastrectomy, cholecystecomy, (currently assessed by radiology but may need be</li> </ul>	vessels of the hepatoduodenal ligament or surgical effort to achieve a complete resection; sfusions or temporary stoma
	INCLUSIONS 2: Decisio	on-making for Interval Debulking Surgery (IDS) follow	wing NACT EXCLUSIONS
•	3 to 4 cycles of neoadjuvant platinum based chemotherapy (no published role after 6 cycles), or equivalent No progressive disease (poor prognosis) In the case of proven non-nodal extra-abdominal disease at diagnosis, the extra-abdominal disease should be resectable Performance status and comorbidity that allows a maximal surgical effort to no residual disease Able to have at least 2 cycles of chemotherapy after surgery	<ul> <li>Likely RD &gt;2cm (which can be difficult to determine preoperatively and warran at laparotomy becomes clear likely RD &gt;2cm). Patients with symptomatic large symptom benefit.</li> <li>No / minimal response to neoadjuvant chemotherapy</li> </ul>	nts attempt but to consider to stop surgery if e masses may still benefit from surgery for gical effort to achieve a complete resection sfusions or stoma
	INCLUSIONS 3: Decision	n-making for Secondary Debulking Surgery post-SACT	EXCLUSIONS
	Only one line of previous chemotherapy	• Under 6 months since last platinum chemotherapy (platinum resistant)	

Only one line of previous chemotherapy
 Complete resection at first surgery
 Performance status zero
 Ascites < or = 500mls OR – any clear cell histology ovarian cancer relapse resectable to zero</li>
 Under 6 months since last platinum chemotherapy (platinum resistant)
 Symptomatic from relapse (not PS 0)
 Comorbidity precluding maximal surgical effort
 Radiological evidence of metastases not accessible to surgical removal (i.e. complete resection not deemed possible)

## North of Scotland Clinical Management Guideline (CMG): Relapsed Ovarian Cancer Last Updated 05/04/2024





Multiple lines of treatment may be required. Choice will depend on a number of factors including previous response, duration of response, previous toxicities and patient preference.



The follow-up schedules for Ovarian Cancer patients in the North of Scotland are indicative-only. Clinical judgement will determine the requirement for follow-up including any further imaging required depending upon patient factors and treatments undertaken.

Ovarian Cancer (Stage 1-4)

		Years 1 & 2	Every 3 months at Gynae-oncology Clinic	
--	--	-------------	---	--

Year 3 - 5 Every 6 months at Gynae-oncology Clinic

Consider discharge at 60 months if no evidence of disease recurrence.

Ongoing access to Gynaecology Clinical Nurse Specialist for symptomatic problems experienced ongoing post-discharge in each North of Scotland board.

Follow-Up to consist of physical exam at Gynae-Oncology Clinic and imaging as clinically indicated.

CA125 should not be performed routinely unless evidence of disease recurrence.

Where there is a recurrence in Ovarian disease, patient follow-up returns to Year 1 after subsequent treatment.

Where appropriate, consider patient initiated follow-up or extended follow-up.



The International Federation of Gynaecology and Obestrics (FIGO) staging (January 2014)

	FIGO Staging			
1A	Tumo	Tumour limited to 1 ovary, capsule intact, no tumour on surface, negative washings.		
1B	Tumo	Tumour involves both ovaries otherwise like IA.		
[Tu		our limited	to 1 or both ovaries]	
10	1Ci	Surgical spill		
1C	1Cii	Capsule rupture before surgery or tumour on ovarian surface		
	1Ciii	iii Malignant cells in the ascites or peritoneal washings		
2A	Extens	sion and/or	r implant on uterus and/or Fallopian tubes	
2B	Extens	Extension to other pelvic intraperitoneal tissues		
	[ Posit	[ Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the pelvis]		
3A	Positive retroperitoneal lymph nodes only		retroperitoneal lymph nodes only	
54	3A1	3A1(i)	Metastasis ≤ 10 mm	
		3A1(ii)	Metastasis > 10 mm	
3A2	Micro	Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes		
3B	Macro	Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen		
3C	Macro	Macroscopic, extrapelvic, peritoneal metastasis > 2 cm ± positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen.		
4A	Pleura	l effusion v	with positive cytology	
4B		Hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)		

4
North Cantor Alliance

Neoadjuvant Carboplatin-paclitaxel (+/- bevacizumab if stage 4 disease) Carboplatin (if not suitable for/intolerant of taxanes)	Primary SACT Carboplatin-paclitaxel + bevacizumab (6 cycles) then bevacizumab (maintenance) + Olaparib (SMC 2368 - homologous recombination deficiency (HRD) positive status defined by either BRCA1/2 mutation and/or genomic instability) Carboplatin or Carboplatin-paclitaxel
<u>Adjuvant</u> Carboplatin-paclitaxel Carboplatin (if not suitable for/intolerant of taxanes) Carboplatin-liposomal doxorubicin	Additional treatment options for advanced disease Topotecan (weekly) Topotecan (days 1-5) Cisplatin Cisplatin-etoposide (Rotterdam) Liposomal doxorubicin (Caelyx)
Maintenance therapy after response to platinum based treatment (platinum sensitive) Olaparib (relapsed disease :- SMC 1047/15/SMC 2367- BRCA mutated) Olaparib (SMC 2368) plus bevacizumab Olaparib (newly diagnosed, advanced - SMC 2209) Rucaparib (relapsed disease - SMC 2224) Niraparib (relapsed disease - SMC 1341/18) Niraparib (advanced disease - SMC 2338)	Relapsed disease (Platinum sensitive i.e. > 6 months post carboplatin) Carboplatin Carboplatin-paclitaxel Carboplatin-liposomal doxorubicin Carboplatin-gemcitabine
Relapsed disease (Platinum resistant i.e. < 6 months post carboplatin) Carboplatin (weekly) Carboplatin – paclitaxel (weekly) Liposomal doxorubicin (Caelyx) Paclitaxel (weekly) Paclitaxel (weekly) + bevacizumab	For carboplatin allergy, consider a cisplatin-containing regimen. For paclitaxel allergy or intolerance, options include docetaxel containing regimen, e.g. carboplatin-docetaxel.

## Endocrine therapy can be considered at all stages if ER positive

North of Scotland Clinical Management Guideline (CMG): Definitions Last Updated 05/04/2024



	<u>Definitions</u>
BSO	Bilateral Salpingo Oophorectomy
СТ	Computerised Tomography
IDS	Interval Debulking Surgery
MDT	Multidisciplinary Team Meeting
MRI	Magnetic Resonance Imaging
NACT	Neo-adjuvant Systemic Anti-Cancer Therapy
NCA	North Cancer Alliance
RMI	Risk of Malignancy Index
SACT	Systemic Anti-Cancer Therapy
ТАН	Total Abdominal Hysterectomy
UFS	Up Front Surgery